Fasenra

Phase 3Small molecule

AstraZeneca

Fasenra is one of 51 small molecule programs targeting Granuloma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GranulomaActive, not recruiting

AsthmaUnknown

COPDActive, not recruiting

GranulomaPhase 2

Active, not recruiting

AsthmaPreclinical

Unknown

COPDPhase 3

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

46 2

Xolair

Roche

Preclinical

25 3

Fasenra

AstraZeneca

Phase 3

1 4

Singulair

AstraZeneca

Preclinical

17 5

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 6

Atrovent

Boehringer Ingelheim

Preclinical

5 7

Symbicort

AstraZeneca

Preclinical

6 8

Aciphex

Akero Therapeutics

Preclinical

2 9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

1 10

Tylenol

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Asthma1 trial

A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT04159519·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fasenra. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fasenra compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fasenra. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

Fasenra

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Asthma1 trial

References

Drug Info

Quick Facts

Related News